AI Engines For more Details: Perplexity Kagi Labs You
Respiratory Effects: Inhalation of high concentrations of carbon dioxide can lead to respiratory symptoms such as shortness of breath, rapid breathing, and chest tightness. Elevated CO2 levels can stimulate the respiratory center in the brain, leading to increased respiratory rate and depth in an attempt to eliminate excess CO2 from the body. Individuals with pre-existing respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), or bronchitis may experience exacerbation of symptoms in environments with high CO2 levels.
Cardiovascular Effects: High levels of carbon dioxide in the bloodstream can lead to respiratory acidosis, a condition characterized by an imbalance in the body's acid-base balance. Respiratory acidosis can cause symptoms such as confusion, drowsiness, headache, and rapid heartbeat. Prolonged exposure to elevated CO2 levels may also increase the risk of cardiovascular events such as arrhythmias, myocardial ischemia, and hypertension in susceptible individuals.
Neurological Effects: Chronic exposure to elevated CO2 levels can impair cognitive function and decision-making abilities due to decreased cerebral blood flow and oxygen delivery to the brain. Symptoms of CO2-induced neurotoxicity may include headache, dizziness, fatigue, difficulty concentrating, and impaired memory. These effects can interfere with daily activities and may pose risks in occupations that require sustained attention and mental acuity.
Sleep Disturbances: High levels of carbon dioxide in indoor environments, particularly during sleep, can disrupt sleep quality and lead to symptoms such as restlessness, insomnia, and daytime fatigue. CO2-induced sleep disturbances may be more pronounced in poorly ventilated or overcrowded spaces where CO2 concentrations can accumulate, such as bedrooms, dormitories, or commercial aircraft cabins.
Work Performance: Prolonged exposure to elevated CO2 levels in indoor environments can impair cognitive function, productivity, and work performance. Studies have shown that increased CO2 concentrations in indoor air can lead to decreased alertness, slower reaction times, and decreased decision-making ability, which may impact job performance and safety in workplaces such as offices, schools, and manufacturing facilities.
Psychological Effects: Chronic exposure to high levels of carbon dioxide may contribute to feelings of discomfort, irritability, and anxiety in susceptible individuals. Indoor environments with poor ventilation and elevated CO2 levels have been associated with increased reports of subjective symptoms such as headaches, dizziness, nausea, and malaise, which can affect mood and well-being.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lactococcus cremoris | Increases |
| species | Lactococcus lactis | Increases |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Allergy to milk products | 0.6 | 0.6 | |
| Ankylosing spondylitis | 0.2 | -0.2 | |
| Anorexia Nervosa | 0.6 | -0.6 | |
| Antiphospholipid syndrome (APS) | 0.2 | -0.2 | |
| Atrial fibrillation | 0.6 | -0.6 | |
| Autism | 0.2 | 0.2 | 0 |
| Barrett esophagus cancer | 0.2 | 0.2 | |
| Carcinoma | 0.2 | -0.2 | |
| Celiac Disease | 0.6 | 0.2 | 2 |
| Cerebral Palsy | 0.2 | -0.2 | |
| Chronic Fatigue Syndrome | 0.2 | 0.6 | -2 |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | -0.2 | |
| Chronic Urticaria (Hives) | 0.2 | -0.2 | |
| Coagulation / Micro clot triggering bacteria | 0.8 | 0.2 | 3 |
| COVID-19 | 0.2 | 0.8 | -3 |
| Crohn's Disease | 0.4 | 0.4 | |
| deep vein thrombosis | 0.8 | 0.8 | |
| Depression | 0.2 | 0.8 | -3 |
| Dermatomyositis | 0.2 | -0.2 | |
| Eczema | 0.2 | 0.2 | |
| Endometriosis | 0.2 | -0.2 | |
| Epilepsy | 0.2 | -0.2 | |
| Functional constipation / chronic idiopathic constipation | 0.4 | 0.4 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.2 | 0.2 | |
| Glioblastoma | 0.2 | 0.2 | |
| Halitosis | 0.2 | 0.2 | |
| Hidradenitis Suppurativa | 0.2 | -0.2 | |
| hypersomnia | 0.4 | 0.4 | |
| hypertension (High Blood Pressure | 0.6 | 0.6 | 0 |
| Inflammatory Bowel Disease | 0.6 | -0.6 | |
| Insomnia | 0.2 | -0.2 | |
| Liver Cirrhosis | 0.6 | 0.6 | 0 |
| Long COVID | 0.8 | -0.8 | |
| Low bone mineral density | 0.4 | -0.4 | |
| ME/CFS with IBS | 0.2 | -0.2 | |
| ME/CFS without IBS | 0.2 | -0.2 | |
| Metabolic Syndrome | 0.6 | 0.6 | 0 |
| Mood Disorders | 0.2 | 0.8 | -3 |
| multiple chemical sensitivity [MCS] | 0.2 | -0.2 | |
| Multiple Sclerosis | 0.2 | 0.2 | 0 |
| Neuropathy (all types) | 0.2 | -0.2 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.8 | -0.8 | |
| Obesity | 0.2 | -0.2 | |
| obsessive-compulsive disorder | 0.2 | -0.2 | |
| Osteoarthritis | 0.2 | -0.2 | |
| pancreatic cancer | 0.2 | -0.2 | |
| Parkinson's Disease | 0.8 | 0.2 | 3 |
| Polycystic ovary syndrome | 0.4 | -0.4 | |
| Psoriasis | 0.2 | -0.2 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1 | 0.2 | 4 |
| Sjögren syndrome | 0.2 | -0.2 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.2 | -0.2 | |
| Systemic Lupus Erythematosus | 0.2 | -0.2 | |
| Type 1 Diabetes | 0.2 | 0.2 | |
| Type 2 Diabetes | 0.2 | 0.6 | -2 |
| Ulcerative colitis | 0.6 | -0.6 | |
| Unhealthy Ageing | 0.2 | -0.2 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.